256
- Kugathasan S, et al. Infliximab retreatment in adults and children with Crohn’s disease:
risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol.
2002;97(6):1408–14. - O'Meara S, Nanda KS, Moss AC. Antibodies to infliximab and risk of infusion reactions in
patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm
Bowel Dis. 2014;20(1):1–6. - Baert F, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s
disease. N Engl J Med. 2003;348(7):601–8. - Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised
trial. Lancet. 2002;359(9317):1541–9. - Hwang SH, et al. Detection of IgE binding component to infliximab in a patient with
infliximab- induced anaphylaxis. Ann Allergy Asthma Immunol. 2014;112(4):393–4. - Jonsson F, et al. Human FcgammaRIIA induces anaphylactic and allergic reactions. Blood.
2012;119(11):2533–44. - Jonsson F, et al. An unexpected role for neutrophils in anaphylaxis. Med Sci (Paris).
2011;27(10):823–5. - Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med. 2001;344(1):30–7.
- Cheifetz A, et al. The incidence and management of infusion reactions to infliximab: a large
center experience. Am J Gastroenterol. 2003;98(6):1315–24. - Lichtenstein L, et al. Infliximab-related infusion reactions: systematic review. J Crohns
Colitis. 2015;9(9):806–15. - Brennan PJ, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients,
from evaluation to treatment. J Allergy Clin Immunol. 2009;124(6):1259–66. - Hong DI, et al. Allergy to monoclonal antibodies: cutting-edge desensitization methods for
cutting-edge therapies. Expert Rev Clin Immunol. 2012;8(1):43–52. quiz 53-4 - Ben-Horin S, et al. Addition of an immunomodulator to infliximab therapy eliminates anti-
drug antibodies in serum and restores clinical response of patients with inflammatory bowel
disease. Clin Gastroenterol Hepatol. 2013;11(4):444–7. - Grosen A, Julsgaard M, Christensen LA. Serum sickness-like reaction due to infliximab rein-
troduction during pregnancy. J Crohns Colitis. 2013;7(5):e191. - Ben-Horin S, et al. The decline of anti-drug antibody titres after discontinuation of anti-
TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther.
2012;35(6):714–22. - Farrell RJ, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab
in Crohn’s disease: a randomized controlled trial. Gastroenterology. 2003;124(4):917–24. - Rahier JF, et al. Severe skin lesions cause patients with inflammatory bowel disease to discon-
tinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8(12):1048–55. - Hellstrom AE, Farkkila M, Kolho KL. Infliximab-induced skin manifestations in patients
with inflammatory bowel disease. Scand J Gastroenterol. 2016;51(5):563–71. - Freling E, et al. Cumulative incidence of, risk factors for, and outcome of dermatological
complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am
J Gastroenterol. 2015;110(8):1186–96. - Fiorino G, et al. Review article: anti TNF-alpha induced psoriasis in patients with inflamma-
tory bowel disease. Aliment Pharmacol Ther. 2009;29(9):921–7. - Kip KE, et al. Tumor necrosis factor alpha antagonist-associated psoriasis in inflamma-
tory diseases: an analysis of the FDA adverse event reporting system. Inflamm Bowel Dis.
2013;19(6):1164–72. - Fiorino G, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease
patients receiving anti-TNF-alpha agents. Autoimmun Rev. 2014;13(1):15–9. - Guerra I, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory
bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6(5):518–23. - George LA, et al. Psoriasiform skin lesions are caused by anti-TNF agents used for the treat-
ment of inflammatory bowel disease. Dig Dis Sci. 2015;60(11):3424–30.
U. Wong and R.K. Cross